Frazier Life Sciences Acquisition Corp. II
Searching since IPO 2026-10-14- CIK 2153598
- FLSC
- IPO 2026-10-14
- 13 filings
- IPO Size
- $75M
- raised at the IPO
- Current Status
- IPO
- from its latest filing
- IPO Year
- 2026
- year it listed
Filings, by quarter
13 filings over 2 quarters; violet bars carry a milestone
- 26 Q3: 2 filings
- 26 Q4: 11 filings
- S-1 filed 26 Q3
- IPO 26 Q4
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
About
A newly formed blank-check company that seeks to complete an initial business combination with an unidentified target. It intends to focus on biotechnology opportunities and finance a company developing important new therapies.
Investment Focus
Biopharmaceuticals
Key Information
As the filings state it
- IPO Date
- 2026-10-14
- Jurisdiction of Incorporation
- Cayman Islands
- SIC
- 6770
- SPAC Ticker
- FLSC
Stock Performance
FLSCTrading symbol, and its price at each step since the first trade
| Point | Date | Price | Move |
|---|---|---|---|
| First Trade | 2026-10-14 | $10.18 | |
| Current Price | 2026-10-14 | $10.29 | +1% |
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
Frazier Life Sciences brings life-sciences venture and public-equity investing experience, including biopharmaceutical investments, company creation and drug-development expertise. Its leadership includes Albert Cha, Kevin Li, Fran Adams and Alexandra (“Ali”) Jackson, supported by independent directors Benjamin L. Palleiko, R. Scott Struthers and William C. Fairey.